Whistleblower Swap Doesn't Kill FCA Standing, 3rd Circ. Says
The Third Circuit on Tuesday reversed the dismissal of a whistleblower suit against Sanofi-Aventis and Bristol-Myers Squibb over their marketing of the anti-coagulant drug Plavix, finding that a partnership formed to...To view the full article, register now.
Already a subscriber? Click here to view full article